查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1424107

多發性硬化症市場、份額、規模、趨勢、產業分析報告：按藥物類型、給藥途徑、地區、細分市場預測，2024-2032 年

Multiple Sclerosis Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Immunosuppressants, Immunomodulators); By Route of Administration; By Region; Segment Forecast, 2024 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 119 Pages | 商品交期: 最快1-2個工作天內

價格

根據 Polaris Market Research 的最新研究，到 2032 年，全球多發性硬化症市場規模預計將達到 335.7 億美元。 該報告提供了對當前市場動態的詳細洞察，並對未來市場成長進行了分析。

知名市場參與者越來越注重研發 (R&D) 來創造創新藥物，這導致了全球市場的擴張。 例如，2020 年 12 月，Adamas Pharmaceuticals Inc. 發表了評估 ADS-5102 的 3 期臨床試驗結果，ADS-5102 是一種研究性金剛烷胺製劑，旨在治療多發性硬化症 (MS) 患者。

產品的推出、政府加強改善治療和護理的機會以及多發性硬化症盛行率的上升預計將推動市場成長。

多發性硬化症對全球的影響日益擴大，越來越引起醫療保健提供者和政府的關注。 這種疾病的盛行率不斷上升，迫使許多國家的政府採取積極措施，包括制定指南和建議。

政府機構也發起了各種宣傳活動，以教育患者了解各種可用的治療方案。

例如，德國多發性硬化症協會在德國經營三到四個產業來幫助多發性硬化症患者。 他們於每年 5 月 31 日組織世界多發性硬化症日會議，旨在消除無障礙障礙並擴大對多發性硬化症患者的支持網絡。

單株抗體在多發性硬化症的治療上越來越受歡迎。 許多公司正在努力利用這些抗體的潛力來開發治療多發性硬化症的新藥。 此外，全球對人源化單株抗體的需求不斷增加，這是一種用於治療多發性硬化症的常見免疫抑制劑。 尤其是羅氏公司推出的Ocrevus，已成為最大的醫藥產品，貢獻了可觀的收入，並為市場的持續成長做出了貢獻。

多發性硬化症市場報告亮點

在多發性硬化症市場中，免疫調節劑領域佔據了最大的銷售份額。 免疫調節劑擴大治療選擇以及治療疾病的新產品的推出正在促進市場成長。

新產品的推出和向口服藥物的轉變是推動該行業成長的主要因素。

北美佔最大的市佔率。 北美地區是百健 (Biogen)、諾華 (Novartis AG) 和賽諾菲 (Sanofi SA) 等公司最重要的市場。 因此，這些公司優先考慮將最新藥物推向市場。

亞太地區的多發性硬化症市場成長最快，而顯著的成長率歸功於製藥公司在該地區分銷網絡的加強。 許多國家正在實施旨在降低多發性硬化症治療相關成本的政府舉措，這是推動該地區多發性硬化症藥物需求的關鍵因素。

目錄

第1章簡介

第 2 章執行摘要

第3章研究方法

第 4 章全球多發性硬化症市場洞察

  • 多發性硬化症市場 - 產業概況
  • 多發性硬化症市場動態
    • 推動者和機會
      • FDA 批准數量的增加將推動市場成長
      • 醫療保健基礎設施投資激增推動市場成長
    • 抑制因素和挑戰
      • 與藥品相關的高成本阻礙了市場成長
  • 杵分析
  • 多發性硬化症產業趨勢
  • 價值鏈分析
  • COVID-19 感染的影響分析

第 5 章全球多發性硬化症市場（依藥物類型）

  • 主要發現
  • 簡介
  • 免疫抑制劑
  • 免疫調節因素

第 6 章全球多發性硬化症市場（依給藥途徑）

  • 主要發現
  • 簡介
  • 注射
  • 口服製劑

第 7 章區域全球多發性硬化症市場

  • 主要發現
  • 簡介
    • 2019-2032 年多發性硬化症市場評估，地區
  • 多發性硬化症市場 - 北美
    • 北美：多發性硬化症市場，依給藥途徑劃分，2019-2032 年
    • 北美：多發性硬化症市場，依藥物類型，2019-2032 年
    • 多發性硬化症市場 - 美國
    • 多發性硬化症市場 - 加拿大
  • 多發性硬化症市場 - 歐洲
    • 歐洲：多發性硬化症市場，依給藥途徑劃分，2019-2032 年
    • 歐洲：多發性硬化症市場，依藥物類型，2019-2032 年
    • 多發性硬化症市場 - 英國
    • 多發性硬化症市場 - 法國
    • 多發性硬化症市場 - 德國
    • 多發性硬化症市場 - 義大利
    • 多發性硬化症市場 - 西班牙
    • 多發性硬化症市場 - 荷蘭
    • 多發性硬化症市場 - 俄羅斯
  • 多發性硬化症市場 - 亞太地區
    • 亞太地區：多發性硬化症市場，依給藥途徑劃分，2019-2032 年
    • 亞太地區：多發性硬化症市場，依藥物類型，2019-2032 年
    • 多發性硬化症市場 - 中國
    • 多發性硬化症市場 - 印度
    • 多發性硬化症市場 - 馬來西亞
    • 多發性硬化症市場 - 日本
    • 多發性硬化症市場 - 印度尼西亞
    • 多發性硬化症市場 - 韓國
  • 多發性硬化症市場 - 中東和非洲
    • 中東和非洲：多發性硬化症市場，依給藥途徑劃分，2019-2032 年
    • 中東和非洲：多發性硬化症市場（以藥物類型），2019-2032 年
    • 多發性硬化症市場 - 沙烏地阿拉伯
    • 多發性硬化症市場 - 阿拉伯聯合大公國
    • 多發性硬化症市場 - 以色列
    • 多發性硬化症市場 - 南非
  • 多發性硬化症市場 - 拉丁美洲
    • 拉丁美洲：多發性硬化症市場，依給藥途徑劃分，2019-2032 年
    • 拉丁美洲：多發性硬化症市場，依藥物類型，2019-2032 年
    • 多發性硬化症市場 - 墨西哥
    • 多發性硬化症市場 - 巴西
    • 多發性硬化症市場 - 阿根廷

第8章競爭態勢

  • 擴張與收購分析
    • 放大
    • 收購
  • 夥伴關係/協作/協議/揭露

第9章公司簡介

  • Hoffmann-La Roche Ltd.
  • Bayer Healthcare AG
  • Teva Pharmaceuticals
  • GlaxoSmithKline
  • AbbVie Inc.
  • Sonafi Pasteur
  • Pfizer Inc
  • Merck & Company
  • Novartis AG
  • AB Science
  • Opexa
Product Code: PM1343

The global multiple sclerosis market size is expected to reach USD 33.57 billion by 2032, according to a new study by Polaris Market Research. The report "Multiple Sclerosis Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Immunosuppressants, Immunomodulators); By Route of Administration; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The increased emphasis on research and development (R&D) for the creation of ground-breaking pharmaceuticals by prominent industry participants is credited with the global market's expansion. For instance, Adamas Pharmaceuticals Inc. announced findings from a phase 3 clinical trial evaluating ADS-5102, an investigational amantadine agent designed to treat patients with multiple sclerosis (MS), in December 2020.

Product introductions, escalating governmental efforts to improve treatment and care accessibility, and the rising incidence of multiple sclerosis are anticipated to drive market growth.

The growing global impact of multiple sclerosis is causing increasing concern among healthcare providers and governments. The disease's rising prevalence has compelled governments in a number of countries to take proactive measures, such as developing guidelines and recommendations.

Also, government organizations are launching a variety of awareness campaigns to educate patients about the various treatment options which are available.

For instance, the German Multiple Sclerosis Society runs three to four industries in Germany to help people with Multiple Sclerosis. They organize a World MS Day competition every May 31st with the goal of removing accessibility barriers and extending the support network for those affected by multiple sclerosis.

Monoclonal antibodies are becoming more popular in the treatment of multiple sclerosis. Many companies are committed to developing new drugs for multiple sclerosis by leveraging the potential of these antibodies. Furthermore, global demand for humanized monoclonal antibodies, a common class of immunosuppressive drugs used to treat multiple sclerosis, is increasing. Particularly, Ocrevus, introduced by F. Hoffmann-La Roche Ltd., has emerged as the biggest drug, contributing to a substantial revenue and contributing to the market's continuous growth.

Multiple Sclerosis Market Report Highlights

The immunomodulators segment held the largest revenue share in the multiple sclerosis market. The expansion of immunomodulator treatment options and the introduction of new products for treating the disease is contribute to the growth of the market.

The oral segment is witnessed for the fastest market growth during the forecast period. owing to the launch of new products and the incline towards the oral drugs are the key factors which bolster the growth of the segment.

North America accounted for the largest market share. The north america is the most important market for companies such as Biogen, Novartis AG, and Sanofi SA. As a result, these companies are prioritizing the introduction of their most recent pharmaceuticals in market.

The Asia-Pacific region witnessed for the fastest growth in the multiple sclerosis market, the substantial growth rate is ascribed to the enhanced distribution networks of an pharmaceutical companies in the region. The growing implementation of government initiatives in a number of countries aimed at lowering the costs associated with MS treatment is a key driver driving the region's demand for MS drugs.

The global key market players include Hoffmann-La Roche Ltd., Bayer Healthcare AG, Teva Pharmaceuticals, GlaxoSmithKline, AbbVie, Inc., Sonafi Pasteur, Pfizer Inc., Merck & Company, Novartis AG, AB Science, and Opexa.

Polaris Market Research has segmented the multiple sclerosis market report based on drug type, route of administration and region:

Multiple Sclerosis, Drug Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Immunosuppressants
  • Lemtarda
  • Ocrelizumab
  • Zinbryta
  • Aubagio
  • Immunomodulators
  • Ampyra
  • Capxone
  • Betaseron/Extavia
  • Gilneya
  • Avonex/Plegridy
  • Tyasabri
  • Rebif
  • Teucifidera

Multiple Sclerosis, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

  • Injectable Agents
  • Oral Agents

Multiple Sclerosis, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Multiple Sclerosis Market Insights

  • 4.1. Multiple Sclerosis Market - Industry Snapshot
  • 4.2. Multiple Sclerosis Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rise in the number of FDA approval will drive the growth of the market
      • 4.2.1.2. Surge in the investment for healthcare infrastructure will bolster the growth of the market
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost associated with the drugs hindering the growth of the market
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Multiple Sclerosis Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Multiple Sclerosis Market, by Drug type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Multiple Sclerosis, by Drug type, 2019-2032 (USD Billion)
  • 5.3. Immunosuppressants
    • 5.3.1. Global Multiple Sclerosis Market, by Immunosuppressants, by Region, 2019-2032 (USD Billion)
    • 5.3.2. Lemtarda
      • 5.3.2.1. Global Multiple Sclerosis Market, by Lemtarda, by Region, 2019-2032 (USD Billion)
    • 5.3.3. Ocrelizumab
      • 5.3.3.1. Global Multiple Sclerosis Market, by Ocrelizumab, by Region, 2019-2032 (USD Billion)
    • 5.3.4. Zinbryta
      • 5.3.4.1. Global Multiple Sclerosis Market, by Zinbryta, by Region, 2019-2032 (USD Billion)
    • 5.3.5. Aubagio
      • 5.3.5.1. Global Multiple Sclerosis Market, by Aubagio, by Region, 2019-2032 (USD Billion)
  • 5.4. Immunosuppressants
    • 5.4.1. Global Multiple Sclerosis Market, by Immunosuppressants, by Region, 2019-2032 (USD Billion)
    • 5.4.2 Ampyra
    • 5.4.21. Global Multiple Sclerosis Market, by Ampyra, by Region, 2019-2032 (USD Billion)
    • 5.4.3 Capxone
      • 5.4.3.1. Global Multiple Sclerosis Market, by Capxone, by Region, 2019-2032 (USD Billion)
    • 5.4.4 Betaseron/Extavia
      • 5.4.4.1. Global Multiple Sclerosis Market, by Betaseron/Extavia, by Region, 2019-2032 (USD Billion)
    • 5.4.5 Gilneya
      • 5.4.5.1. Global Multiple Sclerosis Market, by Gilneya, by Region, 2019-2032 (USD Billion)
    • 5.4.6 Avonex/Plegridy
      • 5.4.6.1. Global Multiple Sclerosis Market, by Avonex/Plegridy, by Region, 2019-2032 (USD Billion)
    • 5.4.7 Tyasabri
      • 5.4.7.1. Global Multiple Sclerosis Market, by Tyasabri, by Region, 2019-2032 (USD Billion)
    • 5.4.8 Rebif
      • 5.4.8.1. Global Multiple Sclerosis Market, by Rebif, by Region, 2019-2032 (USD Billion)
    • 5.4.9 Teucifidera
    • 5.4.91. Global Multiple Sclerosis Market, by Teucifidera, by Region, 2019-2032 (USD Billion)

6. Global Multiple Sclerosis Market, by Route of Administration

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • 6.3. Injectable Agents
    • 6.3.1. Global Multiple Sclerosis Market, by Injectable Agents, by Region, 2019-2032 (USD Billion)
  • 6.4. Oral Agents
    • 6.4.1. Global Multiple Sclerosis Market, by Oral Agents, by Region, 2019-2032 (USD Billion)

7. Global Multiple Sclerosis Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Multiple Sclerosis Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 7.3. Multiple Sclerosis Market - North America
    • 7.3.1. North America: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
    • 7.3.2. North America: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.3.3. Multiple Sclerosis Market - U.S.
      • 7.3.3.1. U.S.: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.3.3.2. U.S.: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.3.4. Multiple Sclerosis Market - Canada
      • 7.3.4.1. Canada: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.3.4.2. Canada: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • 7.4. Multiple Sclerosis Market - Europe
    • 7.4.1. Europe: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
    • 7.4.2. Europe: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.4.3. Multiple Sclerosis Market - UK
      • 7.4.3.1. UK: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.4.3.2. UK: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.4.4. Multiple Sclerosis Market - France
      • 7.4.4.1. France: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.4.4.2. France: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.4.5. Multiple Sclerosis Market - Germany
      • 7.4.5.1. Germany: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.4.5.2. Germany: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.4.6. Multiple Sclerosis Market - Italy
      • 7.4.6.1. Italy: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.4.6.2. Italy: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.4.7. Multiple Sclerosis Market - Spain
      • 7.4.7.1. Spain: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.4.7.2. Spain: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.4.8. Multiple Sclerosis Market - Netherlands
      • 7.4.8.1. Netherlands: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.4.8.2. Netherlands: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.4.9. Multiple Sclerosis Market - Russia
      • 7.4.9.1. Russia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.4.9.2. Russia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • 7.5. Multiple Sclerosis Market - Asia Pacific
    • 7.5.1. Asia Pacific: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
    • 7.5.2. Asia Pacific: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.5.3. Multiple Sclerosis Market - China
      • 7.5.3.1. China: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.5.3.2. China: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.5.4. Multiple Sclerosis Market - India
      • 7.5.4.1. India: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.5.4.2. India: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.5.5. Multiple Sclerosis Market - Malaysia
      • 7.5.5.1. Malaysia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.5.5.2. Malaysia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.5.6. Multiple Sclerosis Market - Japan
      • 7.5.6.1. Japan: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.5.6.2. Japan: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.5.7. Multiple Sclerosis Market - Indonesia
      • 7.5.7.1. Indonesia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.5.7.2. Indonesia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.5.8. Multiple Sclerosis Market - South Korea
      • 7.5.8.1. South Korea: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.5.8.2. South Korea: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • 7.6. Multiple Sclerosis Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
    • 7.6.2. Middle East & Africa: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.6.3. Multiple Sclerosis Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.6.4. Multiple Sclerosis Market - UAE
      • 7.6.4.1. UAE: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.6.4.2. UAE: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.6.5. Multiple Sclerosis Market - Israel
      • 7.6.5.1. Israel: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.6.5.2. Israel: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.6.6. Multiple Sclerosis Market - South Africa
      • 7.6.6.1. South Africa: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.6.6.2. South Africa: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • 7.7. Multiple Sclerosis Market - Latin America
    • 7.7.1. Latin America: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
    • 7.7.2. Latin America: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.7.3. Multiple Sclerosis Market - Mexico
      • 7.7.3.1. Mexico: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.7.3.2. Mexico: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.7.4. Multiple Sclerosis Market - Brazil
      • 7.7.4.1. Brazil: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.7.4.2. Brazil: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
    • 7.7.5. Multiple Sclerosis Market - Argentina
      • 7.7.5.1. Argentina: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
      • 7.7.5.2. Argentina: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Hoffmann-La Roche Ltd.
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Bayer Healthcare AG
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Teva Pharmaceuticals
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. GlaxoSmithKline
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. AbbVie Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Sonafi Pasteur
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Pfizer Inc
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Merck & Company
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Novartis AG
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. AB Science
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. Opexa
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development

List of Tables

  • Table 1 Global Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 2 Global Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 3 Multiple Sclerosis Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 4 North America: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 5 North America: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 6 U.S.: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 7 U.S.: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 8 Canada: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 9 Canada: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 10 Europe: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 11 Europe: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 12 UK: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 13 UK: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 14 France: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 15 France: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 16 Germany: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 17 Germany: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 18 Italy: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 19 Italy: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 20 Spain: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 21 Spain: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 22 Netherlands: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 23 Netherlands: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 24 Russia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 25 Russia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 26 Asia Pacific: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 27 Asia Pacific: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 28 China: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 29 China: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 30 India: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 31 India: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 32 Malaysia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 33 Malaysia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 34 Japan: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 35 Japan: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 36 Indonesia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 37 Indonesia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 38 South Korea: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 39 South Korea: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 40 Middle East & Africa: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 41 Middle East & Africa: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 42 Saudi Arabia: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 43 Saudi Arabia: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 44 UAE: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 45 UAE: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 46 Israel: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 47 Israel: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 48 South Africa: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 49 South Africa: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 50 Latin America: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 51 Latin America: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 52 Mexico: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 53 Mexico: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 54 Brazil: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 55 Brazil: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)
  • Table 56 Argentina: Multiple Sclerosis Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 57 Argentina: Multiple Sclerosis Market, by Drug type, 2019-2032 (USD Billion)

List of Figures

  • Figure 1 Global Multiple Sclerosis Market, 2019-2032 (USD Billion)
  • Figure 2 Integrated Ecosystem
  • Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4 Market by Geography
  • Figure 5 Porter's Five Forces
  • Figure 6 Market by Route of Administration
  • Figure 7 Global Multiple Sclerosis Market, by Route of Administration, 2022 & 2032 (USD Billion)
  • Figure 8 Market by Drug type
  • Figure 9 Global Multiple Sclerosis Market, by Drug type, 2022 & 2032 (USD Billion)
  • Figure 10 Multiple Sclerosis Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 11 Strategic Analysis - Multiple Sclerosis Market